サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1594873

アルキル化剤の世界市場、2024年～2031年

Global Alkylating Agents Market - 2024-2031

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
アルキル化剤の世界市場、2024年～2031年
出版日: 2024年11月21日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

市場概要

アルキル化剤の世界市場は、2023年に60億2,000万米ドルに達し、2031年には78億9,000万米ドルに達すると予測され、予測期間2024年にはCAGR 3.5%で成長する見込みです。

アルキル化剤は、DNAからRNAへの転写を阻害し、それによってタンパク質合成を停止させることによって作用する抗悪性腫瘍薬または抗がん剤のクラス別です。アルキル化剤は、DNA上の水素原子の代わりにアルキル基を置換し、その結果DNA鎖内に架橋を形成し、細胞毒性、変異原性、発がん性の作用をもたらします。この作用はすべての細胞で起こりますが、アルキル化剤はDNA修復の時間がない急速に分裂する細胞に主な影響を及ぼします。がん細胞は最も急速に分裂する細胞であるため、最も影響を受ける細胞の一つです。

がんの有病率の増加は、予測期間中の市場を牽引する要因です。例えば、汎米保健機構（Pan American Health Organization）によると、世界全体では、新たに2,000万人ががんと診断され、1,000万人が死亡すると予想されています。今後20年間で、がんの負担は60％近く増加し、ヘルスケアシステム、個人、地域社会にさらなる負担をかけることになります。

市場力学：

促進要因と抑制要因

がん有病率の増加

がんの負担増と有病率の増加は、世界のアルキル化剤市場の成長における重要な要因になると予想されます。アルキル化剤は、最も一般的な化学療法薬の一種であり、がん細胞内のDNA活性に影響を与えるため、様々ながんの治療において重要です。このアプローチは、多くの悪性腫瘍に見られる急速に増殖する細胞に対して非常に効果的です。ヘルスケアシステムが増加するがん患者の要求を満たそうとする中で、アルキル化薬は様々な悪性腫瘍に対する有効性が確立されているため、化学療法レジメンにおいて今後も重要な役割を果たすであろう。将来的には、アルキル化剤は、患者の転帰を改善することを目的とした全体的な治療レジメンの一部として、がん治療においてより大きな役割を果たすようになると思われます。

がんの負担増と有病率の増加は、世界のアルキル化剤市場の成長を促進する極めて重要な要因です。例えば、米国国立衛生研究所（National Institute of Health）によると、2023年には米国で新たに195万8,310人のがん患者が発生し、60万9,820人が死亡すると予測されています。前立腺がんの罹患率は、20年間減少した後、2014年から2019年にかけて毎年3％上昇し、99,000人の新規症例が追加される結果となった。年間がん罹患率は男女10万人当たり440.5人である（2017年から2021年の症例に基づく）。がん死亡率（がん死亡率）は、年間男女10万人当たり146.0人（2018年から2022年の死亡に基づく）。2024年には、0～19歳の小児および青年14,910人ががんと診断され、1,590人が死亡すると予測されます。

アルキル化剤に関連する毒性の懸念

アルキル化剤に関連する毒性懸念などの要因が、世界のアルキル化剤市場を阻害すると予想されています。例えば、米国国立衛生研究所によると、アルキル化剤の特徴的な毒性は、造血毒性、胃腸毒性、性腺毒性、中枢神経毒性です。消化管への障害は、高用量レジメンで頻繁に起こる毒性です。粘膜炎、口内炎、食道炎、下痢はアルキル化剤の高用量投与、特にメルファランとチオテパの高用量投与後、またはメルファランやチオテパを含むアルキル化剤の併用投与後に起こる。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • がんの罹患率の増加
    • 抑制要因
      • アルキル化剤に関連する毒性の懸念
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • 特許分析
  • SWOT分析
  • DMIの見解

第6章 薬剤クラス別

  • 窒素マスタード
  • ニトロソ尿素
  • アルキルスルホン酸塩
  • トリアジン
  • エチレンイミン

第7章 治療領域別

  • 腫瘍学
  • 免疫学
  • 眼科
  • 皮膚科
  • 消化器内科
  • 泌尿器科
  • その他

第8章 投与経路別

  • 経口
  • 静脈内

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第12章 企業プロファイル

  • Pfizer Inc.
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
  • Baxter
  • Novartis AG
  • Viatris Inc.
  • Merck KGaA
  • Teva Pharmaceuticals USA, Inc.
  • Omicron Pharma
  • Aspen Holdings
  • Kekule Life Sciences Limited
  • Fresenius Kabi USA（*LIST NOT EXHAUSTIVE）

第13章 付録

目次
Product Code: PH8772

Market Overview

The global alkylating agents market reached US$ 6.02 billion in 2023 and is expected to reach US$ 7.89 billion by 2031, growing at a CAGR of 3.5% during the forecast period 2024-2031.

Alkylating agents are a class of antineoplastic or anticancer drugs that act by inhibiting the transcription of DNA into RNA and thereby stopping protein synthesis. Alkylating agents substitute alkyl groups for hydrogen atoms on DNA, resulting in the formation of cross-links within the DNA chain and thereby resulting in cytotoxic, mutagenic, and carcinogenic effects. This action occurs in all cells, but alkylating agents have their primary effect on rapidly dividing cells which do not have time for DNA repair. Cancer cells are among the most affected because they are among the most rapidly dividing cells.

The increasing prevalence of cancer is the driving factor that drives the market over the forecast period. For instance, according to the Pan American Health Organization, globally, there were an expected 20 million new cancer diagnoses and 10 million cancer deaths. Over the next two decades, the cancer burden will rise by almost 60%, putting a further burden on healthcare systems, individuals, and communities.

Market Dynamics: Drivers & Restraints

Increasing prevalence of cancer

The rising burden and increasing prevalence of cancer is expected to be a significant factor in the growth of the global alkylating agents market. Alkylating agents, one of the most common types of chemotherapeutic medications, are important in the treatment of a variety of cancers because they affect DNA activity within cancer cells. This approach is very efficient against rapidly proliferating cells found in many malignancies. As healthcare systems attempt to fulfill the demands of a growing cancer patient population, alkylating drugs will continue to play an important role in chemotherapy regimens due to their established efficacy against a variety of malignancies. In the future, alkylating drugs are likely to play a larger role in cancer treatment as part of holistic therapeutic regimens aiming at improving patient outcomes.

The rising burden and increasing prevalence of cancer are pivotal factors driving the growth of the global alkylating agents market. For instance, according to the National Institute of Health, in 2023, the United States is expected to see 1,958,310 new cancer cases and 609,820 cancer deaths. Prostate cancer incidence climbed by 3% every year from 2014 to 2019, after two decades of reduction, resulting in an additional 99,000 new cases. The annual cancer incidence rate is 440.5 per 100,000 men and women (based on cases from 2017 to 2021). The cancer death rate (cancer mortality) is 146.0 per 100,000 men and women annually (based on deaths from 2018-2022). In 2024, a projected 14,910 children and adolescents between the ages of 0 and 19 will be diagnosed with cancer, with 1,590 deaths from the condition.

Toxicity concerns associated with alkylating agents

Factors such as toxicity concerns associated with alkylating agents are expected to hamper the global alkylating agents market. For instance, according to the National Institute of Health, the characteristic toxicities of the alkylating agents are hematopoietic, gastrointestinal, gonadal, and CNS toxicity. Damage to the gastrointestinal tract is a toxicity that frequently occurs with high-dose regimens. Mucositis, stomatitis, esophagitis, and diarrhea occur with high doses of alkylating agents, particularly after high doses of melphalan and thiotepa or combinations of alkylating agents, including melphalan or thiotepa.

Segment Analysis

The global alkylating agents market is segmented based on drug class, therapy area, route of administration, distribution channel, and region.

Oncology segment is expected to dominate the global alkylating agents market share

Oncology segment is expected to dominate the global alkylating agents market share. The oncology segment is expected to dominate the global alkylating agents market due to the growing prevalence of various cancers and the crucial role these agents play in cancer treatment. Alkylating agents are a type of chemotherapeutic treatment that works by disrupting the DNA of cancer cells, preventing them from reproducing and multiplying. This method works very well against rapidly dividing cells, which include many forms of cancer cells. As cancer continues to be one of the top causes of morbidity and mortality around the world, the demand for effective therapeutic options such as alkylating agents is likely to expand significantly. Top of Form

Several factors contribute to this development, including an increase in the incidence of cancers such as lung, breast, colorectal, and stomach cancer. For instance, according to the World Health Organization (WHO), cancer diagnoses are predicted to exceed 22 million by 2023 and in the case of breast cancer, 1 in 12 women will be diagnosed with breast cancer in their lifetime and 1 in 71 women die of it. underscoring the critical need for better therapeutic strategies. Moreover, alkylating medicines are frequently used in conjunction with other chemotherapy treatments to improve treatment efficacy, making them a standard in cancer procedures.

Geographical Analysis

North America is expected to hold a significant position in the global alkylating agents market share

North America is expected to hold a significant portion of the global alkylating agents market. This is due to the increasing incidence of cancer, technological advancements, advanced healthcare infrastructure, and the presence of major players in the region. As the incidence of cancer rises, so does the demand for effective therapeutic choices, resulting in a greater dependence on known chemotherapeutic medications such as alkylating agents. These medicines have a crucial function in the treatment of many cancers, making them vital in oncology regimens across North American healthcare systems.

For instance, according to an article published by the National Institute of Health, in 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. Cancer mortality continued to decline through 2021, averting over 4 million deaths since 1991 because of reductions in smoking, earlier detection for some cancers, and improved treatment options in both adjuvant and metastatic settings. However, these gains are threatened by increasing incidence for 6 of the top 10 cancers.

Asia Pacific is growing at the fastest pace in the global alkylating agents market

Asia Pacific is experiencing the fastest growth in global alkylating agents owing to the increasing incidence of cancer and technological advancements in the region. For instance, according to the National Institute of Health, the expected number of cancer cases in India for 2022 is 14,61,427 (crude rate: 100.4 per 100,000). In India, one out of every nine people is likely to develop cancer over his or her lifetime. Males and females were most likely to develop lung and breast cancer, respectively.

Competitive Landscape

The major global players in the global alkylating agents market include Pfizer Inc., Baxter, Novartis AG, Viatris Inc., Merck KGaA, Teva Pharmaceuticals USA, Inc., Omicron Pharma, Aspen Holdings, Kekule Life Sciences Limited, Fresenius Kabi USA among others.

Emerging Players

Jazz Pharmaceuticals, Inc., ADC Therapeutics SA., MEI Pharma, Inc. among others

For more details on this report - Request for Sample

Key Developments

  • In May 2024, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor (BTKi).

Why Purchase the Report?

  • To visualize the global alkylating agents market segmentation based on drug class, therapy area, route of administration, distribution channel, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global alkylating agents market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global alkylating agents market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Class
  • 3.2. Snippet by Therapy Area
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Cancer
    • 4.1.2. Restraints
      • 4.1.2.1. Toxicity Concerns Associated with Alkylating Agents
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Patent Analysis
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. By Drug Class

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 6.1.2. Market Attractiveness Index, By Drug Class
  • 6.2. Nitrogen Mustards*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Nitrosoureas
  • 6.4. Alkyl Sulfonates
  • 6.5. Triazines
  • 6.6. Ethylenimines

7. By Therapy Area

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Area
    • 7.1.2. Market Attractiveness Index, By Therapy Area
  • 7.2. Oncology*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Immunology
  • 7.4. Ophthalmology
  • 7.5. Dermatology
  • 7.6. Gastroenterology
  • 7.7. Urology
  • 7.8. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Intravenous

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacy*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacy
  • 9.4. Online Pharmacy
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Area
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. The U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Area
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. UK
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Area
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Area
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Area
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Pfizer Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Baxter
  • 12.3. Novartis AG
  • 12.4. Viatris Inc.
  • 12.5. Merck KGaA
  • 12.6. Teva Pharmaceuticals USA, Inc.
  • 12.7. Omicron Pharma
  • 12.8. Aspen Holdings
  • 12.9. Kekule Life Sciences Limited
  • 12.10. Fresenius Kabi USA (*LIST NOT EXHAUSTIVE)

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us